• Explore /
  • Poster
  • / Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.

Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.

Abstract Poster

Authors

null

Richard S. Finn

David Geffen School of Medicine at UCLA, Los Angeles, CA

Richard S. Finn , Philippe Merle , Alessandro Granito , Yi-Hsiang Huang , Gyorgy Bodoky , Marc Pracht , Osamu Yokosuka , Olivier Rosmorduc , René Gerolami , Chiara Caparello , Roniel Cabrera , Charissa Chang , Weijing Sun , Guohong Han , Marie-Aude Le Berre , Annette Baumhauer , Gerold Meinhardt , Jordi Bruix

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01774344

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 344)

DOI

10.1200/JCO.2017.35.4_suppl.344

Abstract #

344

Poster Bd #

F14

Abstract Disclosures

Similar Posters

First Author: Jordi Bruix

First Author: Richard S. Finn

First Author: Richard S. Finn

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Treatment of hepatocellular carcinoma with tyrosine kinase inhibitors: Real-world outcomes from the West of Scotland.

Treatment of hepatocellular carcinoma with tyrosine kinase inhibitors: Real-world outcomes from the West of Scotland.

First Author: Gregory Naylor